MA57021B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents

Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Info

Publication number
MA57021B1
MA57021B1 MA57021A MA57021A MA57021B1 MA 57021 B1 MA57021 B1 MA 57021B1 MA 57021 A MA57021 A MA 57021A MA 57021 A MA57021 A MA 57021A MA 57021 B1 MA57021 B1 MA 57021B1
Authority
MA
Morocco
Prior art keywords
treatment
antibody
biomarker
level
therapy
Prior art date
Application number
MA57021A
Other languages
English (en)
French (fr)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA57021B1 publication Critical patent/MA57021B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA57021A 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients MA57021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (1)

Publication Number Publication Date
MA57021B1 true MA57021B1 (fr) 2024-05-31

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Country Status (26)

Country Link
US (2) US20190195879A1 (https=)
EP (2) EP3916392B1 (https=)
JP (2) JP7066639B2 (https=)
KR (1) KR102416144B1 (https=)
CN (2) CN115932265B (https=)
AU (1) AU2017272608B2 (https=)
CY (1) CY1124768T1 (https=)
DK (2) DK3916392T3 (https=)
EA (1) EA201892542A1 (https=)
ES (2) ES2981046T3 (https=)
FI (1) FI3916392T3 (https=)
HR (2) HRP20240670T1 (https=)
HU (2) HUE067450T2 (https=)
IL (1) IL263103B2 (https=)
LT (2) LT3916392T (https=)
MA (2) MA57021B1 (https=)
MD (2) MD3465214T2 (https=)
MX (2) MX388502B (https=)
PL (2) PL3916392T3 (https=)
PT (2) PT3916392T (https=)
RS (2) RS62155B1 (https=)
SG (2) SG10201911958SA (https=)
SI (2) SI3916392T1 (https=)
SM (2) SMT202400204T1 (https=)
WO (1) WO2017207574A1 (https=)
ZA (2) ZA201808647B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) * 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
EP4051317A1 (en) * 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
TWI865644B (zh) * 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
US20230014026A1 (en) * 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US20220184208A1 (en) * 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
WO2026024668A1 (en) * 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
US20100167315A1 (en) 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
AU2011329161A1 (en) 2010-11-15 2013-06-27 Medimmune, Llc Combination therapy for B cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
HUE058855T2 (hu) * 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
EP2791165A4 (en) * 2011-12-12 2015-08-05 Pikamab Inc PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
US9139649B2 (en) * 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
JP2017519757A (ja) 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
US10969391B2 (en) 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Also Published As

Publication number Publication date
PL3465214T3 (pl) 2021-12-20
JP2019519770A (ja) 2019-07-11
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
IL263103B1 (en) 2023-06-01
CN115932265B (zh) 2026-04-14
SI3916392T1 (sl) 2024-10-30
EP3916392A1 (en) 2021-12-01
ZA201808647B (en) 2021-05-26
HRP20240670T1 (hr) 2024-09-27
DK3916392T3 (da) 2024-05-21
ZA202100296B (en) 2025-05-28
SMT202100291T1 (it) 2021-07-12
MX2018014702A (es) 2019-10-02
NZ748468A (en) 2025-05-30
MA45124B1 (fr) 2021-05-31
EP3465214B1 (en) 2021-04-28
PT3916392T (pt) 2024-06-04
RS65540B1 (sr) 2024-06-28
MA45124A (fr) 2017-12-07
KR20190013980A (ko) 2019-02-11
DK3465214T3 (da) 2021-05-31
FI3916392T3 (fi) 2024-06-03
PT3465214T (pt) 2021-06-30
ES2981046T3 (es) 2024-10-07
EP3916392B1 (en) 2024-05-01
PL3916392T3 (pl) 2024-09-23
BR112018074603A2 (pt) 2019-03-19
IL263103A (en) 2018-12-31
AU2017272608A1 (en) 2018-12-06
US20220283166A1 (en) 2022-09-08
US20190195879A1 (en) 2019-06-27
CN109313194B (zh) 2022-11-04
MX2021014963A (es) 2022-02-24
CN115932265A (zh) 2023-04-07
HUE054860T2 (hu) 2021-10-28
SG10201911958SA (en) 2020-02-27
MX388502B (es) 2025-03-20
ES2878156T3 (es) 2021-11-18
SG11201810159TA (en) 2018-12-28
MD3916392T2 (ro) 2024-10-31
CA3025823A1 (en) 2017-12-07
RS62155B1 (sr) 2021-08-31
IL263103B2 (en) 2023-10-01
WO2017207574A1 (en) 2017-12-07
SMT202400204T1 (it) 2024-09-16
CN109313194A (zh) 2019-02-05
CY1124768T1 (el) 2022-11-25
HUE067450T2 (hu) 2024-10-28
MD3465214T2 (ro) 2021-09-30
JP2022119764A (ja) 2022-08-17
AU2017272608B2 (en) 2023-08-10
KR102416144B1 (ko) 2022-07-04
LT3916392T (lt) 2024-08-26
JP7511806B2 (ja) 2024-07-08
EA201892542A1 (ru) 2019-06-28
SI3465214T1 (sl) 2021-12-31
LT3465214T (lt) 2021-10-11
JP7066639B2 (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
MA57021B1 (fr) Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
Strasser et al. Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile
Varettoni et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
Zoller et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study
Riches et al. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations
Xu et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
Tembhare et al. Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000
Quartuccio et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study
De Winde et al. Tetraspanin CD37 protects against the development of B cell lymphoma
Melchardt et al. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
Wei et al. Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice
Coffey et al. Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignancies
US10725029B2 (en) Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample
Shinohara et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction
Meuleman et al. Rare variants in complement gene in C3 glomerulopathy and immunoglobulin-mediated membranoproliferative GN
Akhter et al. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series
Chihara et al. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan
Angelot‐Delettre et al. Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis
Mitrovic et al. CD 43 expression is associated with inferior survival in the non‐germinal centre B‐cell subgroup of diffuse large B‐cell lymphoma
Nishi et al. FilGAP, a Rac‐specific Rho GTPase‐activating protein, is a novel prognostic factor for follicular lymphoma
Dehmel et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome
Ilhan et al. Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor‐discontinuation” in chronic myeloid leukemia
Sun et al. Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration
Flinterman et al. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk
HK1211042A1 (en) Inflammation-enabling polypeptides and uses thereof